News

May 5, 2017

Screening Tool Approved to Monitor Immune Response to Immunotherapy in Cancer Patients

News

Cancer Genetics Incorporated announced today that its immuno-oncology (IO) assay, Complete::IO, received Clinical Laboratory Improvement Amendments (CLIA) validation and approval. This new screening tool is intended to provide a fast and accurate ... Read more

May 4, 2017

FDA Fast Tracks Development of Combo Therapy for Non-muscle Invasive Bladder Cancer

News

The U.S. Food and Drug Administration has granted fast track status to Altor Bioscience‘s ALT-803 in combination with bacillus Calmette-Guérin (BCG) for the treatment of patients with non-muscle invasive bladder cancer ... Read more

May 3, 2017May 3, 2017

FDA Approves AstraZeneca’s Imfinzi for Previously Treated Advanced Bladder Cancer Patients

News

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Imfinzi (durvalumab) to treat locally advanced or metastatic urothelial carcinoma, the most common type of bladder cancer. The approval, announced ... Read more

May 2, 2017

Opdivo Approved in Europe to Treat Advanced Squamous Cell Cancer of the Head and Neck

News

Opdivo (nivolumab) has been approved in Europe to treat patients with squamous cell cancer of the head and neck (SCCHN) whose disease has progressed while on, or following, platinum-based chemotherapy. “The ... Read more

April 28, 2017April 28, 2017

PD-1 Expression in Immune T-cells Can Help Define Immunotherapy Strategies for Lung Cancer Patients

News

Researchers have found that blood levels of a subset of immune cells, called CD8+ T-cells, following immunotherapy targeting the PD-1 pathway can help determine the anti-tumor response of lung cancer patients. Their ... Read more

April 27, 2017April 27, 2017

Sellas Testing Galinpepimut-S Vaccine as Potential Therapy in Blood and Solid Cancers

News

Sellas Life Sciences Group is developing the galinpepimut-S vaccine as a potential treatment for patients with cancers ranging from mesothelioma and myeloma to leukemia and ovarian cancer, and is moving forward with ... Read more

April 27, 2017

Latest Results Presented on ARMO’s Lead Immunotherapy Candidate, AM0010

News

Combining ARMO BioSciences‘ AM0010, or PEGylated Interleukin-10, with immune checkpoint inhibitors induces better objective response rates and disease control rates in kidney cancer patients, than any of the drugs alone, according to new data ... Read more

April 24, 2017April 24, 2017

Immunotherapy Pioneer Jim Allison Makes TIME’s List of 100 Most Influential People

News

Dr. Jim Allison, an immuno-oncology pioneer at the University of Texas MD Anderson Cancer Center in Houston, has been named to TIME magazine’s list of the world’s 100 most influential people. Allison ... Read more

April 21, 2017

Opdivo for Head-Neck Cancers Too Costly for UK Patients, NICE Rules

News

Opdivo (nivolumab) likely will not be available for United Kingdom patients with head and neck cancers, because the U.K. cost-benefit agency, the National Institute for Health and Care Excellence (NICE), ... Read more

April 20, 2017

Ignyta’s RXDX-106 Works with Immune Checkpoint Inhibitors to Kill Tumors, Study Shows

News

Ignyta’s RXDX-106 can restore the body’s immune-system response against several types of tumors and work with immune checkpoint inhibitors to kill tumor cells, according to a company presentation at the American Association ... Read more